このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

MedX Health マネジメント

マネジメント基準チェック /24

MedX Health'sの CEO はStephen Lockyerで、 May2023年に任命され、の在任期間は 1.08年です。は、会社の株式の0.041%を直接所有しており、その価値はCA$ 8.05K 。経営陣と取締役会の平均在任期間はそれぞれ3年と6.1年です。

主要情報

Stephen Lockyer

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	1.2yrs
CEOの所有権	0.04%
経営陣の平均在職期間	3yrs
取締役会の平均在任期間	6.2yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Stephen Lockyer

1.2yrs

在職期間

Mr. Stephen Lockyer serves as Director of MedX Health Corp since April 12, 2023 and serves as its Chief Executive Officer since May 11, 2023. He co founded Cornwallis Financial Corporation and serves as it...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Christopher Freeman	Corporate Secretary & Acting CFO	2.3yrs	CA$14.93k	データなし
Michael Druhan	President of Dermatological Services & Products	3.8yrs	CA$273.52k	データなし
Stephen Lockyer	CEO & Director	1.2yrs	データなし	0.041% CA$ 7.0k
Scott Naughton	Managing Director of US Operations	7.6yrs	データなし	データなし

3.0yrs

平均在職期間

経験豊富な経営陣: MDXの経営陣は経験豊富であると考えられます ( 3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Stephen Lockyer	CEO & Director	1.3yrs	データなし	0.041% CA$ 7.0k
David Henniger	Independent Vice Chairman	22.7yrs	データなし	1.35% CA$ 230.9k
Kenneth McKay	Independent Chairman	22.7yrs	データなし	0.33% CA$ 56.4k
Daniel Siegel	Member of Medical Advisory Board	6.2yrs	データなし	データなし
Dennis Reich	Member of Medical Advisory Board	7.4yrs	データなし	データなし
Trevor Champagne	Chairman of Medical Advisory Board	5.9yrs	データなし	データなし
Joe Walls	Member of Medical Advisory Board	no data	データなし	データなし
Per Hall	Member of Medical Advisory Board	no data	データなし	データなし
Edmund Ho	Independent Director	1.3yrs	データなし	4.66% CA$ 795.1k

6.2yrs

平均在職期間

73yo

平均年齢

経験豊富なボード: MDXの取締役会は経験豊富であると考えられます ( 6.1年の平均在任期間)。

MedX Health マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

CEO & Director exercised options to buy CA$1.3m worth of stock.

MedX Health Corp Announces Resignation of Naman Damaghlatrous as Director

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

First quarter 2024 earnings released: CA$0.004 loss per share (vs CA$0.007 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.023 loss per share (vs CA$0.028 loss in FY 2022)

MedX Health Corp announced that it expects to receive CAD 2 million in funding

New major risk - Share price stability

Third quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.006 loss in 3Q 2022)

CEO & Director exercised options to buy CA$1.3m worth of stock.

MedX Health Corp announced that it has received CAD 1.02 million in funding

MedX Health Corp announced that it expects to receive CAD 1.5 million in funding

MedX Health Corp announced that it expects to receive CAD 1.5 million in funding

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 2Q 2022)

New major risk - Share price stability

First quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 1Q 2022)

MedX Health Corp Announces Resignation of Naman Damaghlatrous as Director

Full year 2022 earnings released: CA$0.028 loss per share (vs CA$0.03 loss in FY 2021)

MedX Health Corp announced that it expects to receive CAD 1.5 million in funding from Forest Lane Holdings Limited

Third quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.009 loss in 3Q 2021)

MedX Health Corp announced that it expects to receive CAD 1.5 million in funding from Forest Lane Holdings Limited

Second quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 2Q 2021)

MedX Health Corp announced that it expects to receive CAD 4 million in funding

Full year 2021 earnings released: CA$0.03 loss per share (vs CA$0.019 loss in FY 2020)

MedX Health Corp announced that it expects to receive CAD 4 million in funding

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Chairman of the Board Robert von der Porten has left the company

Second quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.004 loss in 2Q 2020)

COO & MD of Light Therapy Products recently sold CA$53k worth of stock

First quarter 2021 earnings released: CA$0.006 loss per share (vs CA$0.005 loss in 1Q 2020)

MedX Health Corp announced that it expects to receive CAD 2.5 million in funding

Full year 2020 earnings released: CA$0.019 loss per share (vs CA$0.023 loss in FY 2019)

MedX Health Corp. Announces Retirement of Board Members

EMPOWER CLINICS INC. and MedX Health Corporation Announce Memorandum of Understanding to Pilot MedX's Leading-Edge DermSecure Screening Platform At Two Select Empower Clinics Locations in Ontario

MedX Health Corp. Announces the Appointment of Paul Karam as Sales and Marketing Director for Europe, Middle East, Africa (EMEA)

New 90-day high: CA$0.24

MedX Health Corp announced that it expects to receive CAD 4 million in funding

MedX Health Corporation Appoints Trevor Champagne as Chair Medical Advisory Board

Medx Health Corp. Announces the Rollout of DermSecure in the Netherlands

Third quarter 2020 earnings released: CA$0.006 loss per share

MedX Health Corp Announces Board Changes

Medx Health Corp. Appoints Anthony Milonas and Wayne Cockburn as Directors

First half earnings released

MedX Health Corp. Announces Management Appointments

MedX Health Corp announced that it expects to receive CAD 2 million in funding

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24